Mekonos

Alameda, United States

Mekonos creates a proprietary cell-engineering platform designed for cell therapies on a chip.

$25.0M raised

Nov 2021

Series A

Top Investors

30,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Mekonos raised?

Mekonos has raised $25.0M in total funding. The most recent round was Series A. The last funding was announced in November 2021.

Who are Mekonos's investors?

Mekonos's investors include TDK Ventures, Sands Capital Ventures, Novartis, Creative Destruction Lab, S32.

Where is Mekonos headquartered?

Mekonos is headquartered in Alameda, United States.

What does Mekonos do?

Mekonos creates a proprietary cell-engineering platform designed for cell therapies on a chip.

What stage is Mekonos at?

Mekonos is at the Series A stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated November 9, 2021.

MLA

"Mekonos — Funding & Investors." VCBacked, November 9, 2021, https://www.vcbacked.co/company/mekonos. Accessed July 3, 2026.

APA

VCBacked. (2021). Mekonos — Funding & Investors. Retrieved July 3, 2026, from https://www.vcbacked.co/company/mekonos

Wikipedia (cite web)

{{cite web |title=Mekonos — Funding & Investors |url=https://www.vcbacked.co/company/mekonos |website=VCBacked |access-date=July 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated November 9, 2021.